Partner David Rosen was quoted in an article in Regulatory Focus, “FDA Plans Hearing on Biosimilar Competition, Development,” about the U.S. Food and Drug Administration’s plan to hold a public hearing to gather input on how it can facilitate the development of biosimilars and help bring them to market in a timely fashion.
Rosen said the legal issues delaying the launch of biosimilars are outside the FDA’s purview. “That’s in the hands of the courts and the companies that are involved,” he said.
He also said that the FDA could have a greater impact on competition by facilitating the development of more biosimilars, which in turn could lead to lower prices for products with multiple biosimilar competitors.
Rosen said the legal issues delaying the launch of biosimilars are outside the FDA’s purview. “That’s in the hands of the courts and the companies that are involved,” he said.
He also said that the FDA could have a greater impact on competition by facilitating the development of more biosimilars, which in turn could lead to lower prices for products with multiple biosimilar competitors.
People
Related News
July 11, 2025
In the News
Foley Attorneys Assess Critical IP Considerations for Emerging Medical Device Companies
Foley & Lardner LLP attorneys Shabbi Khan, Nate Beaver, Austin Kim, and Jeff Simon authored the Med Device Online article, "Critical Considerations For IP & Patents For Emerging Medical Device Companies."
July 11, 2025
In the News
David Morris Featured for Arrival to Foley's Salt Lake City Office
Foley & Lardner LLP partner David Morris is highlighted across legal press for his recent arrival to the firm.
July 10, 2025
In the News
Ann Marie Uetz Comments on Automotive Supply Chain Approach to Evolving Tariff Environment
Foley & Lardner LLP partner Ann Marie Uetz shared perspective from the automotive supply chain amid the evolving trade environment in the Crain's Detroit article, "Ford, Stellantis tighten terms on suppliers as tariff costs add up."